Epirubicin Market Size - Global Analysis Report 2022 - 2028
表柔比星市场规模预计将从 2021 年的 1.9166 亿美元增至 2028 年的 2.4399 亿美元;预计 2022 年至 2028 年的复合年增长率为 3.60%。
表柔比星是一种蒽环类药物,首次临床试验于 1980 年公布。由于疗效和质量更好,该药物比阿霉素更受青睐。它用于化疗治疗各种癌症。该药物单独使用或联合使用,主要用于治疗乳腺癌、卵巢癌、肝癌、膀胱癌等。该产品通过减缓或阻止体内癌细胞的生长起作用。联合疗法包括氟尿嘧啶、盐酸表柔比星和环磷酰胺 (FEC),其中该产品与氟尿嘧啶和环磷酰胺一起服用。与单一疗法相比,表柔比星的辅助疗法似乎毒性较小。辉瑞公司在美国以商品名 Ellence 销售该产品,在其他国家以 Pharmorubicin 或 Epirubicin Ebewe 销售该产品。2007 年 8 月,该产品失去专利并成为仿制药。该产品由于副作用较大,在癌症治疗中应用范围有限,常见的副作用是心脏、骨髓、血液等。
表柔比星(EPI)成功融入固液纳米颗粒配方中,形成稳定的可吸入雾化悬浮液,用于治疗肺癌。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
表柔比星市场:
复合年增长率(2021 - 2028 年)3.60%- 2021 年市场规模
1.9166 亿美元 - 2028 年市场规模
2.4399 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- 辉瑞公司
- 梯瓦制药工业有限公司
- Salius Pharma 私人有限公司
- 阿海珐制药公司迈兰公司
- Hikma Pharmaceuticals PLC
- 费森尤斯卡比公司
- Miracalus Pharma 私人有限公司
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 10毫克/瓶
- 50毫克/瓶
- 100mg/瓶和200mg/瓶
- 乳腺癌
- 肝癌
- 膀胱癌
- 其他的
- 医院 药店
- 零售药店
- 网上药店
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
表柔比星市场根据 剂量、应用、分销渠道和地域进行细分。按地域划分,市场大致分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。本报告提供了对市场的见解和深入分析,强调了市场趋势和市场动态等参数以及全球领先市场参与者的竞争分析。
市场洞察
癌症发病率上升
表柔比星是属于蒽环类的抗癌药物,用于治疗乳腺癌、胃癌等。它通过攻击手术或放射疗法切除大部分肿瘤细胞后残留的肿瘤细胞来降低复发风险。
根据美国癌症协会的数据,预计 2021 年全球癌症负担将上升至 1.93 万例新病例,2020 年将上升至 1.0 万例死亡病例。根据美国国家癌症研究所的数据,癌症发病率和患病率的上升对全球社会产生了重大影响。根据该研究所的数据,在美国,2020 年有近 1800 人被诊断出患有癌症,约有 606,520 人患上癌症。根据国际癌症研究机构的数据,2020 年乳腺癌发病率为 2,261,419,约占全球癌症病例总数的 11.7%。此外,该疾病在 2020 年造成 684,996 人死亡。因此,与癌症相关的高发病率预计将对市场增长产生重大影响。根据美国疾病控制与预防中心 (CDC) 的数据,美国每年约有 24,500 名男性和 10,000 名女性患肝癌,约有 18,600 名男性和 9,000 名女性死于该病。几十年来,美国人患肝癌的比例一直在上升。肝癌在世界其他地区比在美国更常见。因此,癌症病例的不断增加推动了表柔比星市场的发展。
中东和非洲地区的医疗保健行业仍在发展中;因此,他们面临着 COVID-19 疫情带来的最大挑战。卫生当局担心,抗击 COVID-19 会间接导致包括癌症患者在内的患者死亡人数增加。由于许多医院资源和人员有限,医护人员限制了患者预约,预计低成本地区的患者死亡人数将增加。
然而,2021 年启动的新冠疫苗接种计划在多个国家控制了局势。这些控制传播的努力最终将恢复并恢复疫情后的局势。
促进表柔比星市场增长的发展例子如下:
- 2018 年 4 月,Hikma Pharmaceuticals PLC(Hikma 集团)宣布其全资美国子公司 West-Ward Pharmaceuticals Corp.(West-Ward)已推出 50mg/25mL 和 200mg/100mL 规格的盐酸表柔比星注射液 USP,这是 Ellence 的仿制药。West-Ward 的盐酸表柔比星注射液 USP 是原发性乳腺癌切除术后腋窝淋巴结肿瘤受累患者的辅助治疗组成部分。
表柔比星市场 - 应用洞察
根据应用,表柔比星市场细分为乳腺癌、肝癌、膀胱癌和其他癌症。乳腺癌部分在 2021 年占据了最大的市场份额。预计乳腺癌部分在预测期内将在市场上实现最高复合年增长率,预计同一部分在预测期内将实现最高复合年增长率。20 世纪 70 年代,表柔比星作为治疗转移性乳腺癌的药物上市,目前,它是治疗乳腺癌最活跃的单一药物之一。药物可用于乳腺癌早期,以减少乳腺癌复发的机会。它被广泛用作手术和淋巴结切除患者的辅助治疗。因此,在大多数情况下,这种药物通常与其他药物一起开。在某些情况下,它可以用作阿霉素 (Adriamycin) 的替代品,因为它可能比阿霉素引起的心脏损伤更小。该药物通过静脉注射,通常每三周注射一次或每 28 天注射两次,共 6 个周期。辉瑞公司和山德士(诺华公司旗下的一个部门)等公司在市场上销售该药物。癌症治疗领域不断发展,因此,各家公司都在市场上推出产品。例如,2018 年 4 月,Hikma Pharmaceuticals PLC 推出了盐酸表柔比星注射液 USP,有 50mg/25mL 和 200mg/100mL 等规格。该产品是仿制药,与 Ellence 相当。因此,在预测期内,市场上的产品供应和产品发布可能会促进市场的增长。
表柔比星市场 - 剂量洞察
根据剂量,全球表柔比星市场细分为 10mg/瓶、50mg/瓶、100mg/瓶和 200mg/瓶。50mg/瓶细分市场在 2021 年占据了最大的市场份额;然而,预计 100mg/瓶细分市场在预测期内的复合年增长率最高。表柔比星 50 毫克注射液是一种抗癌剂,用作治疗乳腺癌的辅助药物。它是一种发泡剂,应在合格医生的监督下注射到静脉中。10 毫克表柔比星的效果平均持续 3 至 4 天。在表柔比星市场运营的市场参与者提供不同剂量的表柔比星。例如,辉瑞提供 10 毫克和 50 毫克剂量的盐酸表柔比星。
表柔比星市场 - 分销渠道洞察
根据分销渠道,全球表柔比星市场细分为医院药房、零售药房和在线药房。医院药房部分在 2021 年占据了最大的市场份额。预计同一细分市场在预测期内的市场复合年增长率最高,为 4.0%。医院药房是医疗机构患者护理不可或缺的一部分。医院药房是一个致力于在医院环境中始终如一地维护和加强患者药物护理和药物管理以达到最高标准的领域。医院药房是医院购买、储存、配制、分配、制造、测试、包装和分发药品的主要区域之一。控制医院和其他医疗机构的药品使用是医院药房的主要职责。药品的选择、处方、采购、交付、管理和审查是旨在改善患者预后的目标之一。
表柔比星市场报告范围
报告属性 | 细节 |
---|---|
2021 年市场规模 | 1.9166亿美元 |
2028 年市场规模 | 2.4399亿美元 |
全球复合年增长率(2021 - 2028) | 3.60% |
历史数据 | 2019-2020 |
预测期 | 2022-2028 |
涵盖的领域 | 按剂量
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
表柔比星市场——按地区
根据地域划分,表柔比星市场分为北美洲(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙和欧洲其他地区)、亚太地区(中国、日本、印度、澳大利亚、韩国和亚太其他地区)、中东和非洲(阿联酋、沙特阿拉伯、非洲和中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和中美洲其他地区)。
表柔比星市场 - 公司简介
表柔比星市场主要由辉瑞公司、梯瓦制药工业有限公司、Salius Pharma Pvt Ltd、Areva Pharmaceuticals、Mylan NV、Hikma Pharmaceuticals PLC、Fresenius Kabi AG 和 Miracalus Pharma Pvt. Ltd. 等参与者组成。
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The global epirubicin market on region, is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and the South & Central America. North America held the largest market share for epirubicin in 2021. The United States held the largest market in North America for epirubicin, and the market is expected to grow due to rising prevalence of cancer and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the epirubicin market.
Based on dosage, the global epirubicin market is segmented into 10mg/Vial, 50mg/Vial, 100mg/Vial, and 200mg/Vial. The 50mg/Vial segment held the largest share of the market in 2021, however, 100mg/Vial segment is anticipated to register the highest CAGR in the market during the forecast period.
The epirubicin market majorly consists of the players such as Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Salius Pharma Pvt Ltd; Areva Pharamceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; and Miracalus Pharma Pvt. Ltd.
The elevated risk of adverse effects due to epirubicin is hampering the market's growth.
Factors such as rising prevalence of cancer and increasing awareness regarding cancer are propelling the market growth.
Epirubicin HCl is a class of drugs termed anthracyclines and is primarily used to treat breast cancers after surgical resection. Anthracyclines are an antibiotic isolated from the gram-positive bacteria Streptomyces. They are commonly used as chemotherapy agents and exert their antineoplastic effects by targeting the replication of DNA. Epirubicin HCl is often preferred over anthracycline doxorubicin as it has been shown to have fewer side effects. Epirubicin HCl became FDA-approved as adjuvant therapy for treating axillary node-positive breast cancers following resection under the trade name Ellence in 1999. It is currently manufactured through large-scale semi-synthetic methods using daunorubicin as starting material for its preparation.
The List of Companies - Epirubicin Market
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- Salius Pharma Pvt Ltd
- Areva Pharmaceuticals Mylan N. V.
- Hikma Pharmaceuticals PLC
- Fresenius Kabi AG
- Miracalus Pharma Pvt. Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.